I2O Therapeutics receives strategic investment from Colorcon Ventures

▴ I2O Therapeutics receives strategic investment from Colorcon Ventures
Colorcon will collaborate with i2O to accelerate i2O’s research and development efforts

i2O Therapeutics, an innovative biotech company developing a platform to enable oral delivery of traditionally injectable biological drugs, has received a strategic investment from Colorcon Ventures, the corporate venture fund of Colorcon Inc. In addition to this investment, Colorcon will collaborate with i2O to accelerate i2O’s research and development efforts. i2O previously announced its seed round of financing led by Sanofi Ventures and JDRF T1D Fund in April 2020.

“We welcome Colorcon Ventures as a strategic investor at this pivotal time of company growth,” said Ravi Srinivasan, Ph.D., Chief Executive Officer of i2O Therapeutics.

Founded by a team of researchers from Harvard University, i2O Therapeutics is focused on the development of safe and effective oral formulations of therapies that are conventionally limited to injections, e.g. biologics, large molecules, and peptide-based pharmaceuticals such as insulin. The company’s innovative platform enables drugs that traditionally would not survive the hostile environment of the digestive system to pass through safely by utilizing a unique coating that dissolves in the small intestine, thereby releasing the active drug. i2O’s initial focus is on developing a novel oral formulation for GLP-1 analogs.

“We are excited to collaborate with Colorcon to help advance our ionic liquid technology given their rich history of innovation and expertise in pharmaceutical development,” said Samir Mitragotri, Ph.D., Co-founder of i2O Therapeutics.

“Colorcon Ventures’ strategic focus on technologies that transform conventional delivery pathways aligns well with i2O. The ability to deliver injectable therapies orally has the potential to significantly improve patient adherence and outcomes,” commented Martti Hedman, Colorcon’s Chief Executive Officer.

Dr Ali Rajabi-Siahboomi, Chief Scientific Officer of Colorcon states, “Colorcon's excipients and in-depth pharmaceutical development expertise will help advance the use of ionic liquids for the oral delivery of challenging molecules.”

Tags : #i20Therapeutics #LatestNewsini20Therapeutics4thDec #LatestPharmaNews4thDec #ColorconVentures #HarvardUniversity

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Seminar on RERA: Concerns in Real Estate heldDecember 09, 2023
Commonwealth youth leaders want action, not just rhetoric at COP28December 09, 2023
South India’s biggest Gaushala, Satyam Shivam Sundaram Gau Nivas to conduct Annakut Celebrations on Sunday on the eve of its 23rd AnniversaryDecember 08, 2023
Center for Diagnostics and Telemedicine Introduces Groundbreaking Service – Preliminary Clinical and Technical Testing for Medical SoftwareDecember 08, 2023
FTCCI to hold a Seminar on RERA: Concerns in Real EstateDecember 08, 2023
Adoption of Public Health Strategies and Early Detection Key for Cancer Mitigation: ExpertsDecember 08, 2023
Are online spaces safe for women?December 08, 2023
Prescribing Equality: Tackling Gender Disparities in India's Healthcare LeadershipDecember 07, 2023
Digitalizing Health: Generative AI's Impact Amplified by AWS Cloud in IndiaDecember 07, 2023
Eyes on the Future: Dr. Agarwal's Group Channels Rs 100 Crore for Cutting-edge Eye Hospitals Across KeralaDecember 06, 2023
Organ Transplant Scandal: Apollo Hospital Faces Government InquiryDecember 06, 2023
Breaking Barriers in Cancer Treatment: Max Healthcare's CAR-T Therapy PartnershipDecember 06, 2023
Exploring the Link Between Covid-19 Vaccination and Sudden Cardiac Arrests: ICMR StudyNovember 22, 2023
Powering the Future: China's Biodegradable Wireless System for Bioelectronic InnovationNovember 22, 2023
IMS BHU Pioneers Advanced Cardiac Care: Unveiling Cutting-Edge Technologies for Precise DiagnosisNovember 18, 2023
Inito's $6 Million Boost: Transforming Women's Health with AI-Backed Fertility MonitoringNovember 18, 2023
Madras High Court Advocates for Equality: PG Medical Students to Receive Incentive Marks for COVID-19 DutyNovember 18, 2023
Next-Gen Healthcare: CarePods and AI Redefine the Patient ExperienceNovember 17, 2023
Air Quality Crisis: Alarming Rise in Premature Births Linked to Air Quality in Begusarai, BiharNovember 17, 2023
Limerick Contest-2023: A Celebration of Wit and PoetryNovember 17, 2023